Peak sales lovenox?

How high did Lovenox sales reach?
Lovenox hit a peak of about $1.7 billion in 2013, the highest annual revenue the drug ever achieved. After that year, sales tapered as biosimilar competition grew and newer anticoagulants entered the market.

Why did sales fall after the peak?
The entry of generic enoxaparin products, coupled with the launch of newer oral anticoagulants, cut market share and pressured Sanofi to reduce pricing.

What competitors helped erode Lovenox’s dominance?
Generic enoxaparin makers and newer agents such as apixaban and rivaroxaban directly competed for the same indications, hastening the decline in Lovenox’s top line.

When can patients expect future price changes for Lovenox?
Sanofi’s pricing strategy has shifted toward volume‑based discounts and reimbursement negotiations, but no official price reset is scheduled outside of routine market adjustments.

[1] https://www.drugpatentwatch.com/peak-sales-lovenox/